Drug Development Pipeline
Inhaled Levofloxacin (Quinsair™)
Inhaled levofloxacin (Quinsair™) is a formulation of the antibiotic levofloxacin for the management of chronic lung infections caused by Pseudomonas aeruginosa and other bacteria.
Inhaled levofloxacin has been approved in the European Union and Canada for adults with CF. A Phase 3 trial in the United States has been completed.
The program is sponsored by Horizon Pharma and partially supported by the Cystic Fibrosis Foundation. It was conducted within the Therapeutics Development Network.
Recent Inhaled Levofloxacin (Quinsair™) Studies
Closed to Enrollment
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More